The Technical AnalystExchange: STO Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Gabather AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-11.89% SEK1.815
America/New_York / 17 mai 2024 @ 11:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 34.28 mill |
| EPS: | -0.630 |
| P/E: | -2.88 |
| Earnings Date: | Jun 28, 2024 |
| SharesOutstanding: | 18.89 mill |
| Avg Daily Volume: | 0.0426 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.88 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -2.88 | industry: PE 24.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK0.0772 (-95.75%) SEK-1.738 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 1.552 - 2.09 ( +/- 14.73%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK1.815 (-11.89% ) |
| Volume | 0.134 mill |
| Avg. Vol. | 0.0426 mill |
| % of Avg. Vol | 314.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GABA.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GABA.ST
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.